New drug aims to tame rare immune storms

NCT ID NCT04641442

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase 2 study tests a drug called MAS825 in 17 people with rare genetic conditions that cause severe inflammation. The goal is to see if the drug can prevent disease flares better than a placebo. Participants will be monitored for safety and effectiveness over several periods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MAS825
What this could lead to
If successful, this could provide a new treatment option to control flares in rare, severe autoinflammatory diseases.
What could go wrong
This is a small early-phase trial with only 17 participants, so results may not apply broadly. The drug may not prevent flares or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bambino Gesu Hospital

    Roma, RM, 00165, Italy

  • Centrum detske revmatologie a autoinflamatornich onemocneni

    Prague, CZ, 121 00, Czechia

  • Children´s Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229, United States

  • Great Ormond Street Hospital

    London, WC1N 3JH, United Kingdom

  • Novartis Investigative Site

    Paris, 75970, France

  • Novartis Investigative Site

    Chiba, 266-0007, Japan

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    London, NW3 2QG, United Kingdom

  • Seattle Children´s Hospital

    Seattle, Washington, 98105, United States

  • Texas Children´s Hospital

    Houston, Texas, 77030, United States

  • Ustav Imunologie 2 LF UK a FN Motol

    Prague, 150 06, Czechia